Sign In
Buy IKT
$2.18
-0.1000 (-4.39%)
At Close: Jul 31, 2026
Critical Survey: Inhibikase Therapeutics (NASDAQ:IKT) versus Liminatus Pharma (NASDAQ:LIMN)
02:18am, Friday, 26'th Dec 2025
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both small-cap manufacturing companies, but which is the better investment? We will co
Analyzing Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT)
01:58am, Sunday, 21'st Dec 2025
Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will comp
Financial Analysis: Inhibikase Therapeutics (NASDAQ:IKT) and Liminatus Pharma (NASDAQ:LIMN)
02:30am, Sunday, 07'th Dec 2025
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will compa
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
09:54pm, Thursday, 20'th Nov 2025
WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:12pm, Thursday, 20'th Nov 2025
BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics t
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
04:01pm, Thursday, 20'th Nov 2025
Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibi
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
04:01pm, Friday, 14'th Nov 2025
BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics t
Inhibikase Therapeutics (NYSE:IKT) Trading Down 0.6% – What’s Next?
02:52am, Friday, 24'th Oct 2025
Inhibikase Therapeutics, Inc. (NYSE: IKT - Get Free Report)'s share price fell 0.6% during mid-day trading on Thursday. The company traded as low as $1.50 and last traded at $1.53. 20,281 shares were
Inhibikase Therapeutics (NASDAQ:IKT) versus Prime Medicine (NASDAQ:PRME) Head-To-Head Contrast
01:32am, Wednesday, 22'nd Oct 2025
Prime Medicine (NASDAQ: PRME - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will comp
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
08:00am, Tuesday, 19'th Aug 2025
BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics t
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
04:50pm, Thursday, 14'th Aug 2025
BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics t
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
04:05pm, Wednesday, 14'th May 2025
Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)
08:30am, Monday, 05'th May 2025
NEW YORK , May 5, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Inhibikase Therapeutics, Inc. (NASDAQ: IKT) on behalf of the company's shareholders. The investigation
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
08:00am, Monday, 14'th Apr 2025
BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecul
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
04:01pm, Thursday, 27'th Mar 2025
New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clin
